Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)Javier Martín, Andrés Poveda, Antonio Llombart-Bosch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomasJoan Maurel, Antonio López-Pousa, Ramón de Las Peñas, et al.European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancerIgnace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.The Lancet. Oncology|March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.The Lancet. Oncology|June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trialBradley J Monk, Andrés Poveda, Ignace Vergote, et al.Gynecologic Oncology|August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.Cancers|March 6, 2021
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyJavier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, et al.The Lancet. Oncology|June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialAmit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma StudyJavier Martin-Broto, Antonio López Pousa, Ramón de Las Peñas, et al.Pageof 6